MX370272B - Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer. - Google Patents
Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer.Info
- Publication number
- MX370272B MX370272B MX2016011240A MX2016011240A MX370272B MX 370272 B MX370272 B MX 370272B MX 2016011240 A MX2016011240 A MX 2016011240A MX 2016011240 A MX2016011240 A MX 2016011240A MX 370272 B MX370272 B MX 370272B
- Authority
- MX
- Mexico
- Prior art keywords
- chimeric antigen
- antigen receptors
- cancer immunotherapy
- specific chimeric
- derivedfrom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se un receptor de antígeno quimérico específico de CD123 (CAR 123) caracterizado porque tiene una estructura de polipéptidos que comprende un domino que une un ligando extracelular que comprende una región variable de cadena pesada (VH) y una región variable de cadena ligera (VL) de un anticuerpo anti-CD123 monoclonal, una bisagra Fc?RIIIa, CD6a o IgG1, un dominio transmembrana CD6a, y un dominio citoplásmico incluyendo un domino de señalización zeta CD3 y un dominio co-estimulatorio de 4-1BB, en donde dicha VH comprende las secuencias CDR de las SEQ ID NOS: 67, 68 Y 69 y dicha VL comprende las secuencias CDR de las SEQ ID Nos: 70, 71 y 72.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201470137 | 2014-03-19 | ||
| PCT/EP2015/055848 WO2015140268A1 (en) | 2014-03-19 | 2015-03-19 | Cd123 specific chimeric antigen receptors for cancer immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016011240A MX2016011240A (es) | 2017-01-11 |
| MX370272B true MX370272B (es) | 2019-12-09 |
Family
ID=58702463
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016011240A MX370272B (es) | 2014-03-19 | 2015-03-19 | Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer. |
| MX2019012244A MX2019012244A (es) | 2014-03-19 | 2016-08-30 | Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019012244A MX2019012244A (es) | 2014-03-19 | 2016-08-30 | Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer. |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9944709B2 (es) |
| EP (2) | EP3119807B1 (es) |
| JP (2) | JP6689202B2 (es) |
| KR (1) | KR102157411B1 (es) |
| CN (1) | CN106103490B (es) |
| AU (1) | AU2015233461B2 (es) |
| CA (1) | CA2943008C (es) |
| DK (2) | DK3119807T3 (es) |
| ES (2) | ES2877606T3 (es) |
| HU (1) | HUE045480T2 (es) |
| IL (1) | IL247172B (es) |
| MX (2) | MX370272B (es) |
| PL (1) | PL3119807T3 (es) |
| PT (1) | PT3119807T (es) |
| RU (1) | RU2727290C2 (es) |
| TR (1) | TR201910814T4 (es) |
| WO (1) | WO2015140268A1 (es) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US10689609B2 (en) | 2012-03-15 | 2020-06-23 | Flodesign Sonics, Inc. | Acoustic bioreactor processes |
| US9752113B2 (en) | 2012-03-15 | 2017-09-05 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US10322949B2 (en) | 2012-03-15 | 2019-06-18 | Flodesign Sonics, Inc. | Transducer and reflector configurations for an acoustophoretic device |
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US9745548B2 (en) | 2012-03-15 | 2017-08-29 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US10737953B2 (en) | 2012-04-20 | 2020-08-11 | Flodesign Sonics, Inc. | Acoustophoretic method for use in bioreactors |
| ES2814962T3 (es) | 2013-02-20 | 2021-03-29 | Novartis Ag | Fijación eficaz como objetivo de la leucemia humana primaria utilizando células T modificadas con receptor de antígeno quimérico anti-CD123 |
| US9745569B2 (en) | 2013-09-13 | 2017-08-29 | Flodesign Sonics, Inc. | System for generating high concentration factors for low cell density suspensions |
| US9725710B2 (en) | 2014-01-08 | 2017-08-08 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| CA2943008C (en) | 2014-03-19 | 2021-03-30 | Cellectis | Cd123 specific chimeric antigen receptors for cancer immunotherapy |
| US9744483B2 (en) | 2014-07-02 | 2017-08-29 | Flodesign Sonics, Inc. | Large scale acoustic separation device |
| RU2020117196A (ru) | 2014-08-19 | 2020-10-15 | Новартис Аг | Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей |
| ES2688035T3 (es) | 2014-08-29 | 2018-10-30 | Gemoab Monoclonals Gmbh | Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes |
| US20180002435A1 (en) * | 2015-01-26 | 2018-01-04 | Cellectis | mAb-DRIVEN CHIMERIC ANTIGEN RECEPTOR SYSTEMS FOR SORTING/DEPLETING ENGINEERED IMMUNE CELLS |
| KR20170137079A (ko) | 2015-03-11 | 2017-12-12 | 셀렉티스 | 그것들의 지속을 증가시키기 위한 동종이계 t 세포의 조작 및/또는 환자들 내로 이식 방법들 |
| US9777064B2 (en) | 2015-03-17 | 2017-10-03 | Chimera Bioengineering, Inc. | Smart CAR devices, DE CAR polypeptides, side CARs and uses thereof |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| MX2018001776A (es) * | 2015-08-11 | 2018-06-06 | Cellectis | Celulas para inmunoterapia modificadas geneticamente para dirigirse al antigeno cd38 y para la inactivacion del gen cd38. |
| GB201518136D0 (en) * | 2015-10-14 | 2015-11-25 | Glaxosmithkline Ip Dev Ltd | Novel chimeric antigen receptors |
| DK3368571T5 (da) * | 2015-10-30 | 2024-09-30 | Univ California | Transformerende, vækstfaktor-beta-responsive polypeptider og fremgangsmåder til anvendelse deraf |
| US11052111B2 (en) | 2015-12-08 | 2021-07-06 | Chimera Bioengineering, Inc. | Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses |
| WO2017178586A1 (en) | 2016-04-15 | 2017-10-19 | Cellectis | A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression |
| WO2017178585A1 (en) | 2016-04-15 | 2017-10-19 | Cellectis | A method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| WO2017201019A1 (en) | 2016-05-17 | 2017-11-23 | Chimera Bioengineering, Inc. | Methods for making novel antigen binding domains |
| CN107793481A (zh) * | 2016-08-31 | 2018-03-13 | 南京传奇生物科技有限公司 | 一种靶向人cd123的嵌合受体配体及其应用 |
| EP3858365B1 (en) | 2016-09-01 | 2024-01-31 | Chimera Bioengineering Inc. | Gold optimized car t-cells |
| CN107840889A (zh) * | 2016-09-19 | 2018-03-27 | 上海吉倍生物技术有限公司 | 高亲和力的抗cd123抗体及其应用 |
| KR20190127655A (ko) | 2016-10-19 | 2019-11-13 | 프로디자인 소닉스, 인크. | 음향학에 의한 친화성 세포 추출 |
| CN118581046A (zh) | 2016-11-22 | 2024-09-03 | 新加坡国立大学 | 用于t细胞恶性肿瘤免疫疗法的cd7表达阻滞剂和嵌合抗原受体 |
| US20190350980A1 (en) * | 2017-01-18 | 2019-11-21 | Drk Blutspendedienst Baden-W?Rttemberg-Hessen Gmbh | Compositions and methods for transplant recipient conditioning |
| BR112019017751A2 (pt) | 2017-02-28 | 2020-04-07 | Vor Biopharma, Inc. | composições e métodos de inibição de proteínas de linhagem específica |
| ES2979232T3 (es) * | 2017-03-31 | 2024-09-25 | Cellectis Sa | Células inmunitarias con receptor de antígeno quimérico anti-CD22 universal |
| US11767512B2 (en) | 2017-04-13 | 2023-09-26 | Cellectis | Sequence specific reagents targeting CCR5 in primary hematopoietic cells |
| JP2020517259A (ja) | 2017-04-19 | 2020-06-18 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 操作された抗原受容体を発現する免疫細胞 |
| EP4302768A3 (en) * | 2017-06-22 | 2024-05-01 | Board Of Regents, The University Of Texas System | Methods for producing regulatory immune cells and uses thereof |
| US12178830B2 (en) | 2017-06-30 | 2024-12-31 | Memorial Sloan Kettering Cancer Center | Compositions and methods for adoptive cell therapy for cancer |
| WO2019006468A1 (en) * | 2017-06-30 | 2019-01-03 | Memorial Sloan Kettering Cancer Center | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY |
| CA3068636A1 (en) | 2017-06-30 | 2019-01-03 | Memorial Sloan Kettering Cancer Center | Compositions and methods for adoptive cell therapy for cancer |
| CA3067914A1 (en) | 2017-06-30 | 2019-01-03 | Cellectis | Cellular immunotherapy for repetitive administration |
| JP2021501156A (ja) * | 2017-10-27 | 2021-01-14 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Ｔ細胞疲弊を予防および逆転するためのエピジェネティック標的および転写標的の同定 |
| GB201719169D0 (en) * | 2017-11-20 | 2018-01-03 | Univ College Cardiff Consultants Ltd | Novel T-cell receptor and ligand |
| WO2019104245A1 (en) * | 2017-11-22 | 2019-05-31 | La Jolla Institute For Allergy And Immunology | Use and production of engineered immune cells |
| JP2021507561A (ja) | 2017-12-14 | 2021-02-22 | フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． | 音響トランスデューサドライバ及びコントローラ |
| US12365733B2 (en) | 2017-12-29 | 2025-07-22 | Cellectis | Method for improving production of car T cells |
| EP3757133A4 (en) | 2018-02-11 | 2021-12-01 | Jiangsu Hengrui Medicine Co., Ltd. | ISOLATED ANTIGENIC CHEMICAL RECEPTOR, MODIFIED T LYMPHOCYTE INCLUDING IT AND ASSOCIATED USE |
| US11110125B2 (en) | 2018-02-13 | 2021-09-07 | Chimera Bioengineering, Inc. | Coordinating gene expression using RNA destabilizing elements |
| JP7273421B2 (ja) | 2018-02-21 | 2023-05-15 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用 |
| WO2019183094A1 (en) * | 2018-03-19 | 2019-09-26 | The Regents Of The University Of Michigan | Compositions and methods for t-cell and cytokine activation |
| KR20190141511A (ko) * | 2018-06-14 | 2019-12-24 | 주식회사 녹십자랩셀 | 신규 펩티드, 이를 포함하는 키메라 항원 수용체 및 이를 발현하는 면역 세포 |
| US11389485B2 (en) | 2018-08-28 | 2022-07-19 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| JP7546553B2 (ja) * | 2018-09-20 | 2024-09-06 | レンティジェン・テクノロジー・インコーポレイテッド | 抗ｃｄ１２３免疫療法によりがんを処置するための組成物および方法 |
| CN109266618B (zh) * | 2018-10-18 | 2021-04-23 | 赛元生物科技(杭州)有限公司 | 能够靶向肿瘤细胞的巨噬细胞及其制备方法 |
| CN113286633A (zh) * | 2018-10-30 | 2021-08-20 | 宏观基因有限公司 | 用于治疗血液系统恶性肿瘤的双特异性CD123 x CD3双抗体 |
| WO2020152197A1 (en) * | 2019-01-23 | 2020-07-30 | Miltenyi Biotec B.V. & Co. KG | A combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject |
| JP2022526194A (ja) | 2019-04-10 | 2022-05-23 | エレベートバイオ テクノロジーズ，インコーポレイテッド | Ｆｌｔ３特異的キメラ抗原受容体およびその使用方法 |
| US12516100B2 (en) | 2019-04-12 | 2026-01-06 | Board Of Regents, The University Of Texas System | Methods for producing regulatory B cells and uses thereof |
| JP2022546282A (ja) | 2019-08-18 | 2022-11-04 | キメラ・バイオエンジニアリング，インコーポレーテッド | Ｇｏｌｄ制御導入遺伝子による併用療法 |
| KR20220047381A (ko) | 2019-08-28 | 2022-04-15 | 보르 바이오파마 인크. | Cd123 변형을 위한 조성물 및 방법 |
| JP2023540277A (ja) | 2020-08-28 | 2023-09-22 | ブイオーアール バイオファーマ インコーポレーテッド | Ｃｄ１２３改変のための組成物および方法 |
| CN112079927B (zh) * | 2020-09-18 | 2021-12-28 | 西安桑尼赛尔生物医药有限公司 | 一种cd123结合蛋白、含其的car及其应用 |
| AU2021357841A1 (en) | 2020-10-08 | 2023-06-15 | Affimed Gmbh | Trispecific binders |
| CN112646033B (zh) * | 2020-12-16 | 2022-04-12 | 北京艺妙神州医药科技有限公司 | 靶向cd123的嵌合抗原受体及其用途 |
| CN116635064A (zh) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | 具有适应性受体特异性的嵌合抗原受体系统 |
| JP7623497B2 (ja) | 2020-12-31 | 2025-01-28 | サノフイ | ＮＫｐ４６およびＣＤ１２３に結合する多機能性ナチュラルキラー（ＮＫ）細胞エンゲージャ |
| WO2022266075A1 (en) | 2021-06-14 | 2022-12-22 | Caribou Biosciences, Inc. | Methods and materials for treating cancer using car constructs with an intracellular domain comprising a stap domain and a kinase domain or a stap domain and a phosphatase domain |
| WO2023010126A2 (en) | 2021-07-29 | 2023-02-02 | Vor Biopharma Inc. | Chimeric antigen receptors for treatment of cancer |
| JP2024529381A (ja) | 2021-07-30 | 2024-08-06 | アフィメド ゲーエムベーハー | デュプレックスボディ |
| WO2023020471A1 (en) * | 2021-08-16 | 2023-02-23 | Utc Therapeutics (Shanghai) Co., Ltd. | Cd123-targetting antibodies and uses thereof in cancer therapies |
| US12576135B2 (en) | 2021-09-29 | 2026-03-17 | Chimera Bioengineering, Inc. | Compositions and methods for anti-TnMUC1 gold CAR t-cells |
| KR20240099382A (ko) | 2021-11-03 | 2024-06-28 | 아피메트 게엠베하 | 이중특이적 cd16a 결합제 |
| US20250064933A1 (en) * | 2021-12-30 | 2025-02-27 | St. Jude Children's Research Hospital, Inc. | Chimeric antigen receptors comprising a pdz binding motif |
| WO2023138666A1 (en) * | 2022-01-19 | 2023-07-27 | Utc Therapeutics (Shanghai) Co., Ltd. | Circular rna and use thereof |
| US11590169B1 (en) | 2022-03-02 | 2023-02-28 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD123 immunotherapy |
| TW202413419A (zh) | 2022-05-27 | 2024-04-01 | 法商賽諾菲公司 | 與ｎｋｐ４６和ｂｃｍａ變體結合之具有ｆｃ工程化的自然殺手（ｎｋ）細胞接合物 |
| CN117511882A (zh) * | 2022-08-03 | 2024-02-06 | 浙江大学医学院附属第一医院 | 一种通用型免疫效应细胞及其制备方法和应用 |
| WO2024094004A1 (zh) * | 2022-11-03 | 2024-05-10 | 重庆精准生物技术有限公司 | 靶向cd123的全人源抗体及其应用 |
| EP4680282A1 (en) * | 2023-03-17 | 2026-01-21 | Cartesian Therapeutics, Inc. | Intracellular signaling and costimulatory domains adapted for prolonged expression of chimeric antigen receptors |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| AU6704794A (en) | 1993-04-13 | 1994-11-08 | Sloan-Kettering Institute For Cancer Research | Protection of human bone marrow from high dose antifolate therapy using mutated human dihydrofolate reductase dna |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
| WO1997033988A1 (en) | 1996-03-12 | 1997-09-18 | Sloan-Kettering Institute For Cancer Research | Double mutants of dihydrofolate reductase and methods of using same |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| AU4328801A (en) | 2000-02-24 | 2001-09-03 | Xcyte Therapies Inc | Simultaneous stimulation and concentration of cells |
| EP1620537B1 (en) | 2003-03-14 | 2012-10-24 | Cellectis SA | Large volume ex vivo electroporation method |
| US20070036773A1 (en) * | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| EP2332994A1 (en) | 2009-12-09 | 2011-06-15 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Trispecific therapeutics against acute myeloid leukaemia |
| GB2481983A (en) | 2010-07-12 | 2012-01-18 | Hart Fenton & Co Ltd | A ship including a gas tank room |
| CA2993567C (en) * | 2010-07-21 | 2022-06-28 | Sangamo Biosciences, Inc. | Methods and compositions for modification of a t-cell receptor gene |
| EP2633040B1 (en) | 2010-10-27 | 2019-07-10 | Cellectis | Method for increasing the efficiency of double-strand break-induced mutagenesis |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CA3111953C (en) | 2011-04-05 | 2023-10-24 | Cellectis | Method for the generation of compact tale-nucleases and uses thereof |
| EP2814846B1 (en) * | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| EA201990959A1 (ru) * | 2012-04-11 | 2020-02-10 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| SG10201806573TA (en) | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| US20150017136A1 (en) | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
| ES2814962T3 (es) | 2013-02-20 | 2021-03-29 | Novartis Ag | Fijación eficaz como objetivo de la leucemia humana primaria utilizando células T modificadas con receptor de antígeno quimérico anti-CD123 |
| US9657105B2 (en) * | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| TWI654206B (zh) * | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| EP3808410A1 (en) * | 2013-12-20 | 2021-04-21 | Cellectis | Method of engineering multi-input signal sensitive t cell for immunotherapy |
| CA2943008C (en) * | 2014-03-19 | 2021-03-30 | Cellectis | Cd123 specific chimeric antigen receptors for cancer immunotherapy |
| US20180134795A1 (en) * | 2014-06-17 | 2018-05-17 | Cellectis | Cd123 specific multi-chain chimeric antigen receptor |
| EP3233095A2 (en) * | 2014-12-17 | 2017-10-25 | Cellectis | INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN |
| US20180002435A1 (en) * | 2015-01-26 | 2018-01-04 | Cellectis | mAb-DRIVEN CHIMERIC ANTIGEN RECEPTOR SYSTEMS FOR SORTING/DEPLETING ENGINEERED IMMUNE CELLS |
-
2015
- 2015-03-19 CA CA2943008A patent/CA2943008C/en active Active
- 2015-03-19 TR TR2019/10814T patent/TR201910814T4/tr unknown
- 2015-03-19 US US15/126,540 patent/US9944709B2/en active Active
- 2015-03-19 MX MX2016011240A patent/MX370272B/es active IP Right Grant
- 2015-03-19 ES ES19169002T patent/ES2877606T3/es active Active
- 2015-03-19 DK DK15712105.4T patent/DK3119807T3/da active
- 2015-03-19 WO PCT/EP2015/055848 patent/WO2015140268A1/en not_active Ceased
- 2015-03-19 RU RU2016140855A patent/RU2727290C2/ru active
- 2015-03-19 HU HUE15712105A patent/HUE045480T2/hu unknown
- 2015-03-19 ES ES15712105T patent/ES2740903T3/es active Active
- 2015-03-19 PT PT15712105T patent/PT3119807T/pt unknown
- 2015-03-19 CN CN201580014940.9A patent/CN106103490B/zh active Active
- 2015-03-19 AU AU2015233461A patent/AU2015233461B2/en active Active
- 2015-03-19 JP JP2016558087A patent/JP6689202B2/ja active Active
- 2015-03-19 PL PL15712105T patent/PL3119807T3/pl unknown
- 2015-03-19 DK DK19169002.3T patent/DK3569619T3/da active
- 2015-03-19 EP EP15712105.4A patent/EP3119807B1/en active Active
- 2015-03-19 KR KR1020167029035A patent/KR102157411B1/ko active Active
- 2015-03-19 EP EP19169002.3A patent/EP3569619B1/en active Active
-
2016
- 2016-08-08 IL IL247172A patent/IL247172B/en unknown
- 2016-08-30 MX MX2019012244A patent/MX2019012244A/es unknown
-
2018
- 2018-03-19 US US15/925,182 patent/US10988541B2/en active Active
-
2020
- 2020-04-07 JP JP2020068935A patent/JP6942217B2/ja active Active
- 2020-12-17 US US17/124,971 patent/US11919961B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019012244A (es) | Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer. | |
| WO2015150526A3 (en) | Cd33 specific chimeric antigen receptors for cancer immunotherapy | |
| MX381908B (es) | Receptores de antigenos quimericos de cadena sencilla especificos de anti-cll1 para inmunoterapia de cancer. | |
| MX2017001211A (es) | Receptores de antigenos quimericos ror1 (ntrkr1) especificos para inmunoterapia del cancer. | |
| MX2017001229A (es) | Receptores de antigenos quimericos especificos de egfrviii para inmunoterapia de cancer. | |
| MX2015015182A (es) | Células efectoras inmunitarias modificadas genéticamente con el receptor de antígenos quiméricos específico de cs1. | |
| MX2019001184A (es) | Anticuerpos anti-idiotípicos y métodos relacionados. | |
| WO2017147383A8 (en) | Modified cells for immunotherapy | |
| PH12018501042A1 (en) | Antibodies and antibody fragments for site-specific conjugation | |
| EP4414380A3 (en) | Universal anti-cd22 chimeric antigen receptor engineered immune cells | |
| PH12015502479A1 (en) | Cd19 specific chimeric antigen receptor and uses thereof | |
| MX2020003046A (es) | Anticuerpos anti-hla-a2 y metodos para utilizar los mismos. | |
| MY176294A (en) | Antibodies comprising chimeric constant domains | |
| PH12016502491A1 (en) | Bispecific heterodimeric diabodies and uses thereof | |
| WO2015092024A3 (en) | Method of engineering multi-input signal sensitive t cell for immunotherapy | |
| CL2016002195A1 (es) | Receptor antigénico quimérico car con dominios de unión a antígenos a la región constante del receptor de células t beta | |
| MX2021003704A (es) | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales. | |
| AR104718A1 (es) | Receptores de antígenos quiméricos específicos de anti-gd3 para inmunoterapias contra el cáncer | |
| MX379210B (es) | Acoplador trifuncional de antígeno de células t y métodos y usos del mismo. | |
| MX2021001711A (es) | Proteínas biespecíficas modificadas. | |
| MX2016012713A (es) | Inmunoreceptores especificos de claudina-6 y epitopos de celulas t. | |
| AU2016259730A8 (en) | Claudin-18.2-specific immunoreceptors and T cell epitopes | |
| AU2018338423A1 (en) | Novel anti-HLA-A2 antibodies and uses thereof | |
| MX382952B (es) | Métodos de producción de proteínas de cadena doble en bacterias. | |
| MX2020000595A (es) | Regiones de unión al antígeno contra dominios de fibronectina tipo iii y métodos para su uso. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |